Previous close | 2.8900 |
Open | 2.7200 |
Bid | 2.7900 x 3100 |
Ask | 2.8900 x 2200 |
Day's range | 2.4500 - 2.9900 |
52-week range | 2.1500 - 13.6800 |
Volume | |
Avg. volume | 3,408,168 |
Market cap | 1.279B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Achieved FY2022 financial guidanceFourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectivelyNew genomic health services expected in FY2023Webcast today, May 26, 2022, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the hu
Quarterhill Inc. ("Quarterhill" or "the Company") (TSX: QTRH) (OTCQX: QTRHF) announces that John Karnes has been appointed Chief Financial Officer ("CFO") of the Company effective June 6, 2022. Mr. Karnes will replace Steve Thompson, Wi-LAN Inc.'s CFO, who is currently interim-CFO of Quarterhill.
SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on Thursday, May 26, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter’s financial results and report on business progress. The webcast can be accessed on the day